ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,298 | -13.8% | 379,800 | +10.5% | 0.00% | 0.0% |
| Q2 2023 | $2,667 | +36.0% | 343,700 | -0.1% | 0.00% | +33.3% |
| Q1 2023 | $1,961 | +5.1% | 344,100 | +8.6% | 0.00% | 0.0% |
| Q4 2022 | $1,866 | -99.9% | 316,800 | -21.1% | 0.00% | +50.0% |
| Q3 2022 | $1,284,000 | -36.0% | 401,400 | -10.4% | 0.00% | 0.0% |
| Q2 2022 | $2,006,000 | +71.5% | 447,869 | +104.4% | 0.00% | +100.0% |
| Q1 2022 | $1,170,000 | +202.3% | 219,100 | +733.1% | 0.00% | – |
| Q4 2021 | $387,000 | – | 26,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |